Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 7/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6391368 | 0.97 | ALDH1A1 (0.47) | ALDH1A1NPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL5696883 | 0.93 | ALDH1A1 (0.50) | ALDH1A1NPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL5696948 | 0.77 | MMP13 (0.53) | ALDH1A1NPC1RAB9AMAPK1DRD2 | |
| SCHEMBL6706802 | 0.75 | NPC1 (0.51) | ALDH1A1NPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL6218995 | 0.73 | MEN1 (0.54) | ALDH1A1NPC1RAB9ASMN1; SMN2DRD2 | |
| SCHEMBL6296184 | 0.70 | MAPT (0.51) | ALDH1A1SMN1; SMN2MAPK1DRD2POLB | |
| SCHEMBL6518749 | 0.69 | ALDH1A1 (0.48) | ALDH1A1NPC1RAB9ASMN1; SMN2DRD2 | |
| SCHEMBL23903366 | 0.69 | RAB9A (1.00) | ALDH1A1NPC1RAB9ASMN1; SMN2GAA | |
| SCHEMBL16431115 | 0.69 | NPC1 (0.63) | ALDH1A1NPC1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL6234877 | 0.68 | MAPT (0.48) | ALDH1A1NPC1RAB9ASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492775-A2 | OXO-AZABICYCLIC COMPOUNDS | Warner-Lambert Company LLC (US) | 2005-01-05 | — | — | EP | claimed |
| US-20030220355-A1 | Oxo-azabicyclic compounds | GAUDILLIERE BERNARD (FR) | 2003-11-27 | — | — | US | claimed |
| US-20030216402-A1 | Oxo-azabicyclic compounds | GAUDILLIERE BERNARD (FR) | 2003-11-20 | — | — | US | claimed |
| WO-2003076416-A1 | OXO AZABICYCLIC COMPOUNDS | WARNER-LAMBERT COMPANY LLC (US) | 2003-09-18 | — | — | WO | claimed |
| WO-2003076417-A2 | OXO-AZABICYCLIC COMPOUNDS | WARNER-LAMBERT COMPANY LLC (US) | 2003-09-18 | — | — | WO | claimed |
| EP-1680125-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A LIGAND TO AN ALPHA-2-DELTA RECEPTOR | Warner-Lambert Company LLC (US) | 2006-07-19 | — | — | EP | disclosed |
| US-6894057-B2 | Oxo-azabicyclic compounds | WARNER-LAMBERT COMPANY (US) | 2005-05-17 | — | — | US | disclosed |
| WO-2005002585-A1 | COMBINATION OF AN ALLOSTERIC INHIBITOR OF MATRIX METALLOPROTEINASE-13 AND A LIGAND TO AN ALPHA-2-DELTA RECEPTOR | WARNER-LAMBERT COMPANY LLC (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20050004177-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | WARNER-LAMBERT COMPANY LLC | 2005-01-06 | — | — | US | disclosed |
| EP-1492775-A2 | OXO-AZABICYCLIC COMPOUNDS | Warner-Lambert Company LLC (US) | 2005-01-05 | — | — | EP | disclosed |
| US-6747147-B2 | INHIBITORS OF TYPE-13 MATRIX METTALOPROTEASE. RHEUMATOID ARTHRITIS OR OSTEOARTHRITIS, AS WELL AS CERTAIN PROLIFERATIVE CONDITIONS SUCH AS CANCERS, PARTICULARLY HUMAN BREAST CANCER | WARNER-LAMBERT COMPANY | 2004-06-08 | — | — | US | disclosed |
| US-20030220355-A1 | Oxo-azabicyclic compounds | GAUDILLIERE BERNARD (FR) | 2003-11-27 | — | — | US | disclosed |
| US-20030216402-A1 | Oxo-azabicyclic compounds | GAUDILLIERE BERNARD (FR) | 2003-11-20 | — | — | US | disclosed |
| WO-2003076416-A1 | OXO AZABICYCLIC COMPOUNDS | WARNER-LAMBERT COMPANY LLC (US) | 2003-09-18 | — | — | WO | disclosed |
| WO-2003076417-A2 | OXO-AZABICYCLIC COMPOUNDS | WARNER-LAMBERT COMPANY LLC (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216402-A1 | Oxo-azabicyclic compounds | MMP13, CYP2A13, XDH | ALDH1A1 1015/4885NPC1 760/4885RAB9A 3590/4885 |
| US-20050004177-A1 | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | MMP13, MMP10, MMP11 | ALDH1A1 3321/4885NPC1 3853/4885RAB9A 3127/4885 |
| US-20030220355-A1 | Oxo-azabicyclic compounds | MMP13, CYP2A13, CA13 | ALDH1A1 1159/4885NPC1 990/4885RAB9A 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.